Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.49 |
| ▸ | TUBB | P07437 | 2/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24150010 | 1.00 | KEAP1 (0.53) | KEAP1NFE2L2HSP90AA1NPC1RAB9A | |
| SCHEMBL15056513 | 0.86 | NFE2L2 (0.51) | KEAP1NFE2L2HSP90AA1NPC1RAB9A | |
| SCHEMBL15056515 | 0.86 | NFE2L2 (0.51) | KEAP1NFE2L2HSP90AA1NPC1RAB9A | |
| SCHEMBL9944609 | 0.79 | MEN1 (0.58) | KEAP1NFE2L2HSP90AA1NPC1RAB9A | |
| SCHEMBL9817994 | 0.79 | MEN1 (0.58) | KEAP1NFE2L2HSP90AA1NPC1RAB9A | |
| SCHEMBL24149480 | 0.79 | NR4A2 (0.41) | KEAP1NFE2L2NPC1MEN1KMT2A | |
| SCHEMBL2181667 | 0.79 | NR4A2 (0.41) | KEAP1NFE2L2NPC1MEN1KMT2A | |
| SCHEMBL11999774 | 0.79 | NPC1 (0.62) | KEAP1NFE2L2HSP90AA1NPC1RAB9A | |
| SCHEMBL30317323 | 0.79 | NPC1 (0.62) | KEAP1NFE2L2HSP90AA1NPC1RAB9A | |
| SCHEMBL12501248 | 0.78 | NPC1 (0.39) | KEAP1NFE2L2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579325-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921547-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2668177-B1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8772305-B2 | Substituted pyridinyl-pyrimidines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-2668177-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518999-B2 | Modulators of TNF-αsignaling | GENZYME CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| WO-2012101013-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | FERRER INTERNACIONAL S.A. (ES) | 2007-02-22 | — | — | US | disclosed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | GENZYME | 2006-08-03 | — | — | US | disclosed |
| US-7034031-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-6969728-B2 | Antiinflammatory agents | GENZYME CORPORATION (US) | 2005-11-29 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20020119988-A1 | Antiinflammatory agents | GENZYME CORPORATION | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023502-A1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | ADORA1, P2RY1, P2RY11 | KEAP1 2479/4885NFE2L2 929/4885HSP90AA1 4483/4885 |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | GABRB1, GABRA1, GABRB2 | KEAP1 1095/4885NFE2L2 816/4885HSP90AA1 1992/4885 |
| US-20020119988-A1 | Antiinflammatory agents | TNF, TNFRSF1A, CD40 | KEAP1 1557/4885NFE2L2 280/4885HSP90AA1 569/4885 |
| US-20040171617-A1 | treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer | TNF, TNFRSF1A, CD40 | KEAP1 781/4885NFE2L2 324/4885HSP90AA1 693/4885 |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | KEAP1 3000/4885NFE2L2 941/4885HSP90AA1 523/4885 |
| US-20060173010-A1 | Modulators of TNF-alpha signaling | TNF, TNFRSF1A, TNFRSF9 | KEAP1 3000/4885NFE2L2 941/4885HSP90AA1 523/4885 |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | ALK, ACVR1, ALKBH5 | KEAP1 1243/4885NFE2L2 3317/4885HSP90AA1 4381/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | KEAP1 702/4885NFE2L2 1144/4885HSP90AA1 579/4885 |
| US-20130310388-A1 | Modulators of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | KEAP1 3000/4885NFE2L2 941/4885HSP90AA1 523/4885 |
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRM1, GRIK5 | KEAP1 3292/4885NFE2L2 3032/4885HSP90AA1 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.